Search Bar & Filters
Found 11 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying adults newly diagnosed with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancers who are starting systemic cancer treatments such as chemotherapy or immune checkpoint inhibitors. The purpose is to understand how cannabis and cannabinoid use relates to cancer-related symptoms over one year. This observational study enrolls 2000 participants to explore these associations in community oncology settings. Participants do not receive any experimental treatments but complete surveys and have their medical records reviewed. Assessments occur monthly for up to 12 months, capturing cannabis use, perceived benefits and harms, and adverse effects alongside symptom tracking. There is an optional sub-study for some participants receiving immune checkpoint inhibitors at specific cancer centers. During the study, participants complete monthly surveys either online at home, in clinic, or other locations, and their medical records are reviewed for treatment and symptom information. Researchers measure cancer-related symptoms and cannabis use patterns over time. The study monitors participants for up to one year to evaluate symptom changes and cannabis-related effects, with no intervention administered by the study team.
Actively Recruiting
Researchers are evaluating a treatment approach for early-stage hormone-sensitive, HER-2 negative breast cancer with an Oncotype recurrence score of 18 or less. This Phase III trial compares breast conservation surgery with endocrine therapy alone against breast conservation surgery with both radiation and endocrine therapy. The goal is to see if skipping radiation after lumpectomy is not worse in preventing cancer recurrence in the same breast. Participants will be randomly assigned to one of two groups. One group will receive radiation therapy to the breast plus at least five years of endocrine therapy with drugs such as Tamoxifen, Anastrozole, Letrozole, or Exemestane. The other group will receive endocrine therapy only for at least five years without radiation. Radiation must start within 12 weeks of surgery if assigned. Endocrine therapy dosing and schedule are determined by the treating doctor. During the study, participants will have regular follow-ups up to five years to monitor cancer recurrence in the breast and elsewhere, survival, and breast preservation. Assessments will include clinical exams, imaging like mammograms or MRI, and pathology reviews. The main outcome is time to invasive or noninvasive breast tumor recurrence within five years. Some measures will continue through an average of 15 years, including breast conservation rates. Safety and overall health will be monitored throughout and after treatment.
Actively Recruiting
Researchers are studying younger breast cancer survivors who experience elevated depressive symptoms to compare digital mindfulness meditation programs. This phase III clinical trial evaluates two digital methods a live instructor-led program over Zoom and a self-paced app-based program. The study aims to find which digital approach best improves mental health and well-being after completing primary cancer treatment. Participants are randomly assigned to one of three groups a live online mindfulness group meeting weekly for six weeks via Zoom a self-paced app-based mindfulness program with lessons and exercises unlocked sequentially or a meditation-only control group using guided audio meditations. All participants will have access to the mindfulness meditation app throughout the study, including six months of follow-up. Devices and internet access are provided to those who need them. During the study, participants will attend group sessions or use the app according to their assigned group and complete daily mindfulness practice. Researchers will track engagement and measure depressive symptoms at two weeks, three to six months, and six months after the intervention. They will also assess fatigue and explore factors influencing treatment effects and cost-effectiveness. The total study duration spans the six-week intervention plus six months of follow-up.
Actively Recruiting
Researchers are evaluating whether adding adjuvant chemotherapy to ovarian function suppression plus endocrine therapy improves invasive breast cancer-free survival in premenopausal women with early-stage estrogen receptor-positive, HER2-negative breast cancer and specific recurrence scores. This Phase III trial addresses a critical need for better treatment options in younger women, who face higher risks of breast cancer recurrence and mortality. Participants will receive one of two treatment approaches ovarian function suppression combined with an aromatase inhibitor for five years, or chemotherapy followed by the same hormonal treatment. The choice of chemotherapy, aromatase inhibitor, and ovarian suppression method is determined by the investigator, with options such as goserelin, leuprolide, or triptorelin administered monthly or every three months. Endocrine therapy beyond five years is at the investigators discretion, and bilateral oophorectomy may replace ovarian suppression if desired. During the trial, participants will be monitored for invasive breast cancer-free survival over 11 years following randomization. Additional outcomes include overall survival, disease-free survival, distant recurrence, and treatment-related symptoms such as menopausal effects and pain during aromatase inhibitor therapy. The study involves regular assessments to evaluate these outcomes and ensure participant safety throughout the extended follow-up period.
Actively Recruiting
Researchers are evaluating whether simply observing patients after surgery is as effective as continuing pembrolizumab treatment in preventing cancer recurrence in people with early-stage triple-negative breast cancer TNBC who had a complete response after receiving chemotherapy plus pembrolizumab before surgery. This Phase III trial aims to determine if stopping pembrolizumab post-surgery can maintain recurrence-free survival while potentially improving quality of life and reducing treatment burden. Participants are randomly assigned to one of two groups after finishing chemotherapy with pembrolizumab and surgery. One group continues pembrolizumab intravenously every 3 or 6 weeks for 27 weeks. The other group undergoes observation without further pembrolizumab for the same period. Throughout the study, patients have tumor biopsies and blood collected, along with imaging such as mammography, breast ultrasound, or MRI during follow-up. Participants will be monitored for recurrence-free survival and overall survival for up to 10 years. The study also assesses adverse events, quality of life, financial impact, and work productivity at about 27 weeks after starting the assigned treatment or observation. Safety and treatment effects are tracked through biopsies, imaging, blood tests, and patient questionnaires during the study and follow-up.
Actively Recruiting
Researchers are evaluating the effectiveness of two treatment regimens involving ramucirumab combined with paclitaxel or the FOLFIRI regimen leucovorin calcium, fluorouracil, and irinotecan hydrochloride in patients with advanced or treatment-resistant small bowel adenocarcinoma. This phase II randomized study aims to determine which regimen better controls disease progression and assess overall response, survival, and safety. The study also explores how changes in CEA levels may relate to treatment outcomes and collects tissue and blood samples for future research. Participants are randomly assigned to one of two treatment groups. In the first group, patients receive ramucirumab intravenously on days 1 and 15 and paclitaxel intravenously on days 1, 8, and 15 of each 28-day cycle. In the second group, patients receive irinotecan and leucovorin intravenously on days 1 and 15, with fluorouracil given as an intravenous bolus on days 1 and 15 and continuous infusion over days 1-3 and 15-17. Treatment cycles repeat every 28 days until disease progression or unacceptable side effects occur. After treatment ends, participants are followed every 8 weeks until disease progression and then every 6 months for up to three years. During the study, participants undergo evaluations including tumor assessments within specific time frames before starting treatment. Researchers monitor progression-free survival, overall survival, treatment response, and adverse events up to three years after registration. Regular follow-up visits assess health status and disease progression. Participants provide medical history, physical exams, and laboratory tests before enrollment, and specimen banking is offered for additional research. This comprehensive monitoring helps evaluate the safety and effectiveness of the treatments over time.
Actively Recruiting
Researchers are evaluating treatments for men with metastatic prostate cancer, a condition where cancer has spread beyond the prostate to other parts of the body. This phase III trial compares standard systemic therapy alone versus standard systemic therapy combined with definitive treatment of the primary tumor, such as prostate removal surgery or radiation therapy. The goal is to see if adding these local treatments improves survival and delays cancer progression. Participants begin with an induction period of 22 to 28 weeks receiving one of six forms of standard systemic therapy, which may include hormone therapies like goserelin or leuprolide injections, oral medications such as abiraterone or bicalutamide, or chemotherapy with docetaxel. After induction, participants are randomly assigned to continue systemic therapy alone or to receive systemic therapy plus prostatectomy within 8 weeks or radiation therapy within 4 weeks. The study includes tissue and blood sample collection for future research. Throughout the trial, participants have regular assessments including physical exams, laboratory tests measuring PSA and testosterone levels, and imaging scans to monitor disease status. Patient-reported quality of life related to urinary function, pain, and physical abilities is also evaluated over several years. After treatment, participants are followed for up to eight years to track overall survival, progression-free survival, and local symptom progression, providing a comprehensive understanding of treatment effects over time.
Actively Recruiting
Researchers are evaluating the addition of stereotactic body radiation therapy SBRT to the usual treatment for patients with locally advanced, inoperable non-small cell lung cancer that has spread to nearby tissue or lymph nodes. This phase III trial compares the effect of SBRT combined with conventional image guided radiation therapy IGRT, chemotherapy, and subsequent immunotherapy or targeted therapy to the usual treatment alone. The goal is to see if adding SBRT improves overall survival and progression-free survival. Participants are randomly assigned to one of two groups. Arm I receives conventional IGRT with chemotherapy regimens including paclitaxel, carboplatin, pemetrexed, cisplatin, or etoposide during radiotherapy, followed by consolidation immunotherapy with durvalumab or targeted therapy with osimertinib. Arm II receives SBRT to the primary tumor plus conventional IGRT to nodal metastases along with the same chemotherapy and consolidation treatments. Imaging with CT or PETCT scans is used during follow-up. During the study, participants undergo regular assessments including scans and pulmonary function tests at baseline and at 6 and 12 months after radiation therapy. Researchers also collect patient-reported outcomes and monitor quality of life, adverse events, and changes in lung function over time. Biospecimens and advanced imaging data are collected for further analysis. Participants are followed every 3 months for the first year, then every 6 months for years 2 and 3, and yearly thereafter, for up to 13 years total.
Actively Recruiting
Researchers are evaluating the addition of BMX-001, a manganese superoxide dismutase mimetic, to usual symptom management compared to usual symptom management alone to reduce oral mucositis in patients receiving chemoradiation for head and neck cancer. This phase II trial focuses on patients undergoing chemoradiation who often experience painful mouth sores and inflammation as side effects. BMX-001 aims to neutralize harmful substances and reduce damage to normal tissues during treatment. Participants are randomly assigned to one of two groups. Both groups receive cisplatin chemotherapy and intensity-modulated radiation therapy daily for 7 weeks per standard care. One group receives placebo injections, while the other group receives BMX-001 subcutaneously starting before radiation and cisplatin, then twice weekly for 8 weeks. Imaging with CT or MRI and optional blood sample collections are performed throughout the study. During the study, participants complete questionnaires and are monitored for oral mucositis severity, duration, and related symptoms like dry mouth and skin irritation. Follow-up visits occur at 1, 2, 3, 6, 12, and 24 months after treatment. Researchers also assess toxicity, survival outcomes, pain medication use, and collect samples for future research. The primary outcome is the incidence of severe oral mucositis from the start of radiation through 4 weeks after treatment completion.
Actively Recruiting
Researchers are evaluating how measuring circulating tumor DNA ctDNA in blood may help identify patients with urothelial cancer who need additional immunotherapy after surgical removal of the bladder, kidney, ureter, or urethra. This phase IIIII trial studies whether treatments with immunotherapy drugs nivolumab and relatlimab can improve survival and prevent cancer from returning in these patients. Participants are assigned to one of two groups based on their ctDNA test results after surgery. Those with detectable ctDNA receive either nivolumab alone or nivolumab combined with relatlimab intravenously every 28 days for up to 12 cycles. Participants without detectable ctDNA are randomized to receive nivolumab immediately or to undergo ctDNA surveillance and start nivolumab only if ctDNA becomes detectable. Throughout the study, patients undergo tissue and blood collections, imaging scans like CT or MRI, and may have cystoscopy. During the trial, participants are monitored with blood tests, tissue sampling, imaging, and questionnaires to assess cancer recurrence, survival, and quality of life. Researchers measure outcomes such as ctDNA clearance, overall survival, and disease-free survival over up to 5 years after treatment. Safety and side effects are also tracked. Follow-up visits occur regularly after treatment completion to continue monitoring health and disease status.
1-10 of 11
1